(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 11.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Incyte's revenue in 2024 is $3,695,649,000.On average, 9 Wall Street analysts forecast INCY's revenue for 2024 to be $932,225,298,620, with the lowest INCY revenue forecast at $902,145,982,304, and the highest INCY revenue forecast at $948,045,858,651. On average, 9 Wall Street analysts forecast INCY's revenue for 2025 to be $1,037,906,603,704, with the lowest INCY revenue forecast at $1,005,472,906,410, and the highest INCY revenue forecast at $1,073,621,076,780.
In 2026, INCY is forecast to generate $1,159,317,086,685 in revenue, with the lowest revenue forecast at $1,116,905,223,736 and the highest revenue forecast at $1,204,582,676,720.